...
首页> 外文期刊>Diabetes, Obesity and Metabolism >Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and β-cell damage in diabetic mice
【24h】

Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and β-cell damage in diabetic mice

机译:长期服用新型有效,特异性和底物选择性DPP IV抑制剂DSP-7238可改善糖尿病小鼠的血糖控制和β细胞损伤

获取原文
获取原文并翻译 | 示例

摘要

Aims: The purpose of this study is to assess the in vitro enzyme inhibition profile of DSP-7238, a novel non-cyanopyrrolidine dipeptidyl peptidase (DPP) IV inhibitor and to evaluate the acute and chronic effects of this compound on glucose metabolism in two different mouse models of type 2 diabetes.
机译:目的:本研究的目的是评估DSP-7238(一种新型的非氰基吡咯烷二肽基肽酶(DPP)IV抑制剂)的体外酶抑制谱,并评估该化合物对两种不同葡萄糖代谢的急性和慢性作用。 2型糖尿病的小鼠模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号